Impact Partnership Wealth LLC Buys 1,539 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT)

Impact Partnership Wealth LLC raised its stake in shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT) by 8.8% during the 4th quarter, Holdings Channel reports. The fund owned 19,078 shares of the company’s stock after purchasing an additional 1,539 shares during the period. Impact Partnership Wealth LLC’s holdings in Adaptive Biotechnologies were worth $114,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of ADPT. Millennium Management LLC boosted its position in Adaptive Biotechnologies by 1,008.3% during the 2nd quarter. Millennium Management LLC now owns 9,262,341 shares of the company’s stock valued at $33,530,000 after acquiring an additional 8,426,580 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. lifted its holdings in shares of Adaptive Biotechnologies by 12.1% during the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 7,733,884 shares of the company’s stock valued at $39,597,000 after purchasing an additional 834,253 shares during the last quarter. Clearline Capital LP purchased a new stake in shares of Adaptive Biotechnologies during the 3rd quarter valued at $3,147,000. Point72 Asset Management L.P. purchased a new stake in shares of Adaptive Biotechnologies during the 3rd quarter valued at $2,537,000. Finally, Rubric Capital Management LP lifted its holdings in shares of Adaptive Biotechnologies by 2.9% during the 3rd quarter. Rubric Capital Management LP now owns 14,400,000 shares of the company’s stock valued at $73,728,000 after purchasing an additional 400,000 shares during the last quarter. Institutional investors own 99.17% of the company’s stock.

Analysts Set New Price Targets

ADPT has been the subject of several analyst reports. Piper Sandler increased their price objective on Adaptive Biotechnologies from $6.00 to $7.00 and gave the company an “overweight” rating in a report on Monday, November 11th. BTIG Research increased their price objective on Adaptive Biotechnologies from $8.00 to $9.00 and gave the company a “buy” rating in a report on Wednesday, December 18th.

Adaptive Biotechnologies Price Performance

Shares of ADPT stock opened at $7.99 on Friday. The firm has a market capitalization of $1.18 billion, a price-to-earnings ratio of -5.96 and a beta of 1.47. The business has a fifty day moving average of $6.31 and a 200 day moving average of $5.26. Adaptive Biotechnologies Co. has a 1 year low of $2.28 and a 1 year high of $8.33.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.